(Q46090981)

19 December 2017

title

Cyclin E overexpression enhances cytokine-mediated apoptosis in MCF7 breast cancer cells (English)

1 reference

19 December 2017

1 reference

Dhillon NK

1

1 reference

19 December 2017

Mudryj M

series ordinal

2

1 reference

19 December 2017

publication date

1 July 2003

1 reference

19 December 2017

published in

Genes and Immunity

1 reference

19 December 2017

volume

4

1 reference

19 December 2017

page(s)

336-342

1 reference

19 December 2017

issue

5

1 reference

19 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.gene.6363973

exact match

0 references

cites work

BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

Expression of NPAT, a novel substrate of cyclin E-CDK2, promotes S-phase entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

Cyclin E and survival in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

The machinery of programmed cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

Clinical studies of Bcl-2 and treatment benefit in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

Immunologic mechanisms of antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

Shared pathways: death receptors and cytotoxic drugs in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

Process of apoptosis induced by TNF-alpha in murine fibroblast Ltk-cells: continuous observation with video enhanced contrast microscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

Adenovirus-mediated TNF-alpha gene transfer induces significant tumor regression in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

Death the Fas way: regulation and pathophysiology of CD95 and its ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

Caspases: key players in programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

Apoptosis control by death and decoy receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

Regression of human mammary adenocarcinoma by systemic administration of a recombinant gene encoding the hFlex-TRAIL fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

Cell-specific induction of apoptosis by microinjection of cytochrome c. Bcl-xL has activity independent of cytochrome c release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

The potential of TRAIL for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

Potential and caveats of TRAIL in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

TRAIL/Apo-2L: mechanisms and clinical applications in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

Cell cycle regulation of the E2F transcription factor involves an interaction with cyclin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

21 January 2018

Laser scanning cytometry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

Use of flow and laser-scanning cytometry in analysis of cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

7 January 2021

Cyclin E in human cancers.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

7 January 2021

Variation of bcl-2 expression in breast ducts and lobules in relation to plasma progesterone levels: overexpression and absence of variation in fibroadenomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

7 January 2021

Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

7 January 2021

Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

7 January 2021

TRAIL: a molecule with multiple receptors and control mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

7 January 2021

Estrogen-dependent and independent activation of the P1 promoter of the p53 gene in transiently transfected breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363973

7 January 2021

Identifiers

DOI

10.1038/SJ.GENE.6363973

1 reference

19 December 2017

PubMed ID

12847548

1 reference

19 December 2017